Â÷Àç°ü ¸íÀÇ

ºÎ»ê ¡¤ ¿ï»ê ³úÁ¹Áß ÀÀ±Þ½Ã½ºÅÛ Á¤¸³

Â÷Àç°ü ¸íÀÇ

  • ¼Ò ¼Ó
    µ¿¾Æ´ëÇб³º´¿ø ½Å°æ°ú
  • Àü¹®ºÐ¾ß
    ±Þ¼º±â ³úÁ¹Áß Ä¡·á, µÎÅë, ¾îÁö·³Áõ, Ç÷°ü¼º Ä¡¸Å

ÁÖ¿ä Áø·á ºÐ¾ß´Â ±Þ¼º±â³úÁ¹Áß Ä¡·áÀÌ´Ù. ±Þ¼º±â³ú°æ»ö ȯÀÚµéÀÇ Ç÷¼ÒÆÇ º¯È­ ¹× ÀÌ¿¡ µû¸¥ ¿°Áõ º¯È­¿¡ ÀÔ°¢ÇØ Ä¡·á ¹æ¹ýÀ» Àû¿ëÇϰí ÀÖÀ¸¸ç, ±Þ¼º³úÁ¹Áß È¯ÀÚ Ä¡·á ½Ã½ºÅÛ°ú ±Þ¼º±â³ú°æ»öÀÇ ¿µ»óÀû Áø´Ü ¹æ¹ýÀ» °³¹ßÇß´Ù. ±Þ¼º³úÁ¹Áß È¯ÀÚ º´¿ø Àü ´Ü°è ÀÌ¼Û ½Ã°£ ´ÜÃàÀ» À§ÇØ ¿¬±¸Çϰí ÀÖ´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • ÇѾç´ë ÀÇ´ë Çлç
  • ÇѾç´ë ÀÇ´ë ¼®»ç
  • ÇѾç´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) µ¿¾Æ´ëº´¿ø ½Å°æ°ú ±³¼ö
  • úÞ) ±Ç¿ª½É³úÇ÷°üÁúȯ¼¾ÅÍ ³úÇ÷°ü¼¾ÅÍ ¼¾ÅÍÀå
  • úÞ) ±Ç¿ª½É³úÇ÷°üÁúȯ¼¾ÅÍ ±Ç¿ª¼¾ÅÍÀå

ÇÐȸȰµ¿

Academic activities
  • ´ëÇѳúÁ¹ÁßÇÐȸ ÁúÇâ»óÀ§¿øÀå
  • ´ëÇѽŰæ°úÇÐȸ Á¤µµ°ü¸®ÀÌ»ç
  • ´ëÇÑ ³úÁ¹Áß ÇÐȸ ÀÌ»ç (2007)
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 0°Ç
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 5°Ç
Á¦ ¸ñ Regional Cerebral Blood Volume Ratio on Perfusion MRI on the Growth of Infarct Size in Acute Ischemic Stroke European Neurology
¹ßÇ¥³âµµ 2009 ¹ßÇ¥Áö 62(5): 281-286
Á¦ ¸ñ ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy
¹ßÇ¥³âµµ 2008 ¹ßÇ¥Áö European Journal of Neurology, 15(12): 1304-1308
Á¦ ¸ñ Factors related to progression of middle cerebral artery stenosis determined using transcranial Doppler ultrasonograhy
¹ßÇ¥³âµµ 2008 ¹ßÇ¥Áö Journal of Thrombosis and Thrombolysis, 25(3): 265-269
Á¦ ¸ñ Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke
¹ßÇ¥³âµµ 2004 ¹ßÇ¥Áö Platelets, 15(1):3-7
Á¦ ¸ñ Serial measurement of surface expressions of CD63, P-selectin and CD40 ligand on platelets in atherosclerotic ischemic stroke. A possible role of CD40 ligand on platelets in atherosclerotic ischemic stroke
¹ßÇ¥³âµµ 2003 ¹ßÇ¥Áö Ceebrovascular Diseases, 16(4):376-382.

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

µ¿¾Æ´ëÇб³º´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
051-240-2000
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

µ¿¾Æ´ëÇб³º´¿øÀº ¡®½Å·Ú, ºÀ»ç, Àΰ£¾Ö¡¯¸¦ ±âº» À̳äÀ¸·Î 1990³â °³¿øÇÏ¿© ÇöÀç 36°³ Áø·á°ú, 30¿©°³ÀÇ Àü¹®¼¾ÅÍ, 100¿©°³ÀÇ Æ¯¼öŬ¸®´Ð, 1000¿© º´»ó¼ö¸¦ °®Ãß°í ºÎ»êÁö¿ªÀÇ ´ëÇ¥Àû ´ëÇк´¿ø À¸·Î ÀÚ¸®¸Å±èÇÏ¿´½À´Ï´Ù. 2023³â¿¡´Â ºÎ¿ï°æ »ç¸³ ´ëÇк´¿ø ÃÖÃÊ·Î ESG °æ¿µÀ» ¼±Æ÷ÇÏ¿© ģȯ°æÀûÀÎ º´¿ø ½Ã½ºÅÛ ±¸Ãà, »çȸ°øÇå´Ü Ȱ¼ºÈ­¸¦ ÅëÇÑ »çȸÀû ¿ªÇÒÁõ´ë ¹× °í°´ ģȭÀû ¿î¿µÀ» ÅëÇÏ¿© Áö¿ª»çȸ¿Í »ó»ýÇÏ´Â Áö¼Ó°¡´ÉÇÑ ¹ßÀüÀ» µµ¸ðÇϰí ÀÖ½À´Ï´Ù.

µ¿¾Æ´ëÇб³º´¿ø À̹ÌÁö

ºÎ»ê±¤¿ª½Ã ¼­±¸ ´ë½Å°ø¿ø·Î 26 µ¿¾Æ´ëÇб³º´¿ø

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä